Pentoxifylline for the treatment of infection with human immunodeficiency virus.

Pentoxifylline for the treatment of infection with human immunodeficiency virus.
复制标题

己酮可可碱用于治疗人类免疫缺陷病毒感染。

DOI:
--
复制
发表时间:
1994
影响因子:
11.8
通讯作者:
Bruce J. Dezube
Bruce J. Dezube
中科院分区:
医学1区
文献类型:
--
作者:
Bruce J. Dezube

文献摘要

参考文献

被引文献

相似文献

人类免疫缺陷病毒1型(HIV-1)感染中的细胞因子失调已在许多研究中记录,并被认为是这种逆转录病毒感染发病机制的重要组成部分。因此,已建议对细胞因子失调进行药理学修饰作为HIV-1感染的治疗方式。Beth Israel医院(波士顿)的Dezube博士简要回顾了我们关于喷替福林对肿瘤坏死因子-α表达的影响的知识状况,肿瘤坏死因子-α是一种已知影响HIV-1复制的细胞因子,并在该病毒晚期感染的临床表现中发挥可能的作用。三取代黄嘌呤衍生物,已被用于降低血液粘度,并被大多数药物接受者合理地耐受。Dezube博士进行的许多初步研究结果表明,将这种药物与抗逆转录病毒化合物结合使用,可能有助于治疗HIV-1感染患者。
Cytokine dysregulation in human immunodeficiency virus type 1 (HIV-1) infection has been documented in numerous studies and has been cited as an important component in the pathogenesis of this retroviral infection. Pharmacological modification of cytokine dysregulation, therefore, has been suggested as a therapeutic modality for HIV-1 infection. Dr. Dezube of Beth Israel Hospital (Boston) concisely reviews the state of our knowledge regarding the effects of pentoxifylline on expression of tumor necrosis factor-alpha, a cytokine known to influence HIV-1 replication and to play a possible role in the clinical manifestations of advanced infection with this virus. Pentoxifylline, a trisubstituted xanthine derivative, has been used to decrease blood viscosity and is reasonably well tolerated by most recipients of the drug. Results of preliminary studies, many of which were conducted by Dr. Dezube, suggest that use of this agent in combination with antiretroviral compounds may prove useful in the treatment of patients with HIV-1 infection.
己酮可可碱 (Trental) 可减少人外周血单核细胞和培养的 T 细胞中 1 型人类免疫缺陷病毒的复制。
DOI: --
发表时间: 1991
期刊: Blood
影响因子: 20.3
作者:
Fazely,F;Dezube,BJ;Allen-Ryan,J;Pardee,AB;Ruprecht,RM
通讯作者: Ruprecht,RM
DOI: --
发表时间: 1993
期刊: Journal of acquired immune deficiency syndromes
影响因子: --
作者:
Dezube,BJ;Pardee,AB;Chapman,B;Beckett,LA;Korvick,JA;Novick,WJ;Chiurco,J;Kasdan,P;Ahlers,CM;Ecto,LT
通讯作者: Ecto,LT
使用恒定剂量塞替派递增己酮可可碱剂量的 I 期试验。
DOI: --
发表时间: 1990
期刊: Cancer research
影响因子: 11.2
作者:
Dezube,BJ;Eder,JP;Pardee,AB
通讯作者: Pardee,AB